EZH2 and soft tissue sarcoma: Given that resistance to doxorubicin was associated with an expansion of the CSC population and we found that inhibition of the epigenetic modulator EZH2 led to an ablation of the stem cell phenotype, we asked whether co-treatment of soft tissue sarcoma lines with doxorubicin and Tazemetostat would be more effective than either treatment alone.